Pfenex Inc. Through its Reagent Proteins Business Division, Establishes Clinical Supply Agreement With Henry M. Jackson Foundation
Pfenex will supply cGMP-grade CRM197 carrier protein to produce a new conjugate vaccine product, which will be tested in human clinical trials. In addition, Pfenex will grant access to a Biologics Master File that will be filed with the U.S. Food and Drug Administration to support regulatory submissions.
"We are pleased to enter into this agreement with the Henry M. Jackson Foundation and to have Pfenex CRM197 carrier protein to be used in the potential development of a new vaccine that can aid in protecting America's armed forces against tropical diseases," stated Patrick K. Lucy, Vice President, Business Development at Pfenex Inc. "Along with our recently announced contract awarded by the U.S. Department of Health and Human Services (HHS) / Biomedical Advanced Research and Development Authority (BARDA), in which Pfenex will develop a next-generation anthrax vaccine, this agreement demonstrates how Pfenex is leveraging our advanced protein expression platform to support multiple areas of vaccine research and development in both complex antigen production and the supply of key conjugate vaccine carrier proteins."
About Reagent Proteins
Reagent Proteins is a leading supplier of reagent, pre-clinical and cGMP-grade proteins to the biopharmaceutical and vaccine development community. We ensure that scientists have ready access to a comprehensive offering of high-quality proteins to enable their development efforts to proceed efficiently. For more information, please visit www.reagentproteins.com
About Pfenex Inc.
Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information, please visit www.pfenex.com
SOURCE Pfenex Inc.